Brief: Eisai And Biogen Announce U.S. Availability Of Leqembi Iqlik (Lecanemab-Irmb) Subcutaneous Injection Maintenance Dose For Treatment Of Early Alzheimer’S Disease
06/10/2025 23:40
Oct 6 (Reuters) - Eisai Co Ltd 4523.T: EISAI AND BIOGEN ANNOUNCE U.S. AVAILABILITY OF LEQEMBI® IQLIK™ (LECANEMAB-IRMB) SUBCUTANEOUS INJECTION MAINTENANCE DOSE FOR TREATMENT OF EARLY ALZHEIMER’S DISEASE Source text: ID:nGNX3BNwzf Further company coverage: 4523.T ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eisai
See all newsBiogen tops quarterly estimates on rare-disease drug strength (updated)
Biogen beats third-quarter results on strength in rare disease drugs
Brief: FDA Approves Belzutifan-Lenvatinib Combination for Advanced Renal Cell Carcinoma With A Clear Cell Component
Leqembi Pen (Subcutaneous Formulation Of Leqembi) Approved In Japan
Leqembi (Lecanemab) Subcutaneous Formulation As An Initiation Treatment For Early Alzheimer's Disease Approved In China